



World Health  
Organization

WORLD



AMR

AWARENESS WEEK

18-24 NOVEMBER

**Save the date**

# HEPATITIS C DRUG RESISTANCE WEBINAR


Wednesday, 22 November 2023, 13:00-14:30 CET

[Click here to register in advance](#)



PREVENTING ANTIMICROBIAL  
RESISTANCE TOGETHER

# Awareness of hepatitis C drug resistance as access to hepatitis C diagnosis and treatment expands




## Background

World Antimicrobial Resistance Awareness Week (WAAW) is a worldwide campaign that takes place every year to increase awareness and understanding of antimicrobial resistance. WAAW is organized by WHO's Antimicrobial Resistance Division (ARM). The campaign aims to promote best practices among the general public, One Health stakeholders, and policymakers, who all have a crucial role to play in preventing the emergence and spread of antimicrobial resistance. The Department of Global HIV, Hepatitis, and STI Programmes (HHS) has participated in WAAW since 2020 with the most relevant current HIV drug resistance topics. A novel contribution of HSS in the 2023 WAAW edition will be a workshop on awareness of hepatitis C drug resistance.

As diagnosis and treatment of hepatitis C expand to achieve global hepatitis elimination goals, we have a unique opportunity to optimise hepatitis C treatment through maximising population-level outcome and prevention and responding to possible emergence of drug-resistant hepatitis C. This webinar will advocate for a comprehensive response to viral hepatitis drug resistance. The current knowledge, research gaps and public health implications of hepatitis C drug resistance in limited settings will be reviewed. Finally, the WHO's plan to develop an integrated GAP linking drug resistance prevention, monitoring, and response activities at all levels for HIV, viral hepatitis and sexually transmitted infections will be presented.

# Agenda:



| Time        | Topic                                                                                                                                                                                           | Speaker/Facilitator                                                                                                                                                                                                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:00-13:10 | Opening remarks                                                                                                                                                                                 | <b>Meg Doherty</b><br>Director, Department of Global HIV, Hepatitis and STI Programmes, WHO<br><br><b>Silvia Bertagnolio</b><br>Unit Head, Control and Response Strategies, Antimicrobial Resistance Division, WHO |
| 13:10-13:25 | Hepatitis C drug resistance in resource limited settings: Current knowledge, research gaps and public health implications                                                                       | <b>Geoffrey Dusheiko</b><br>University College London, UK                                                                                                                                                          |
| 13:25-13:40 | Prevalence of post-treatment drug resistance in HCV-infected patients failing WHO recommended direct acting agents for initial treatment and re-treatment: systematic review and meta-analyses  | <b>Seth Inzaule</b><br>Department of Global HIV, Hepatitis and STI Programmes, WHO                                                                                                                                 |
| 13:40-13:55 | Advocacy and awareness as part of a comprehensive response to hepatitis C drug resistance                                                                                                       | <b>Danjuma Adda and Rachel Halford</b><br>World Hepatitis Alliance                                                                                                                                                 |
| 13:55-14:10 | Overview of the Global Action Plan on HIV drug resistance 2017-2021 - how its structure may inform thinking around development of key aspects of a hepatitis drug resistance global action plan | <b>Michael Jordan</b><br>Department of Global HIV, Hepatitis and STI Programmes, WHO                                                                                                                               |
| 14:10-14:25 | Comments and Q&A                                                                                                                                                                                | <b>Moderator: Nishi Prabdhial Singh</b> , National Institute for Communicable Diseases, South Africa                                                                                                               |
| 14:25-14:30 | Closing remarks                                                                                                                                                                                 | <b>Philippa Easterbrook</b><br>Department of Global HIV, Hepatitis and STI Programmes, WHO                                                                                                                         |